Lisocabtagene maraleucel

Indications and Usage

Lisocabtagene maraleucel is indicated for the treatment of

• Adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: 
  • Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or 
  • Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or 
  • Relapsed or refractory disease after two or more lines of systemic therapy. 
    Limitations of Use: Lisocabtagene maraleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.
• Adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
  This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
• Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 
• Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.

Side effects needing medical attention

The most common adverse reactions in Breyanzi-treated patients were fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy (damage or disease that affects the brain) , infections, decreased appetite, diarrhea, low blood pressure (hypotension), tachycardia (heart rate over 100 beats per minute), dizziness, cough, constipation, abdominal pain, vomiting, edema (swelling), fever (100.4°F/38°C or higher), tremor, aphasia, delirium (included in the most common neurologic toxicities (≥5%), dyspnea, chills/shaking chills, confusion, difficulty speaking or slurred speech.